Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference
![](https://servier.us/wp-content/uploads/2023/04/bandeau_visuel-46-300x97.png)
Discover our news
Servier Acquires non-Hodgkin B-cell Lymphoma Treatment PIXUVRI® (pixantrone) from CTI BioPharma, Strengthening the Servier Oncology Portfolio
Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients
Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO
Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
Servier and MBC BioLabs Announce Winner of the 2019 Servier Golden Ticket
Servier Showcases Robust Presence at ASCO 2019
Agios to Present Clinical Data from its IDH Program at ASCO
Servier Cuts Ribbon on New Boston Headquarters